Drug intelligence / Profile preview

insulin lispro protamine + insulin lispro

Development stage
Unknown
Lead developer
Eli Lilly
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous
01

Overview

Insulin lispro protamine + insulin lispro is a premixed insulin analog formulation consisting of a rapid-acting insulin analog (insulin lispro) and an intermediate-acting insulin analog (insulin lispro protamine). This combination is designed to provide both prandial (mealtime) and basal (background) glycemic control in patients with diabetes mellitus. The insulin lispro component acts quickly to manage postprandial glucose spikes, while the protamine-crystallized component provides a prolonged duration of action. This specific product is a biosimilar candidate of Humalog Mix, developed through a collaboration between Tonghua Dongbao Pharmaceutical and Nanjing King-Friend Biochemical Pharmaceutical, intended for global markets including the United States.

Brand names
Gulailin 25Gulailin25Gulailin-25Gulailin 50Gulailin50Gulailin-50
Other names
insulin lispro protamine suspension and insulin lispro injectionbiphasic insulin lispropremixed insulin lispro
02

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on insulin lispro protamine + insulin lispro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on insulin lispro protamine + insulin lispro.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call